Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how
JNCI Cancer Spectrum · 2024
DOI: 10.1093/jncics/pkae096 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Giulia Maneri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Germ-Line Mutation, Genetic Testing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The majority of tumor comprehensive genomic profiling (CGP) currently does not include a matched normal control. The use of a tumor-only CGP approach needs the development of a strategy to refine germline pathogenic/likely pathogenic variants (gP/LPVs) calls, so as to limit the performance of unnecessary germline reflex tests and instead successfully identify patients who are carriers of likely gP/LPVs. Guidelines have been developed for the identification of gP/LPVs in BRCA1/2 genes on the basis of tumor-only CGP results and for the evaluation of the appropriateness of performing germline reflex BRCA1/2 testing. In this study, an algorithm to assist decision-making for germline reflex testing of BRCA1/2 variants following tumor-only CGP is proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Genomics Research Core Facility, Gemelli Science and Technology Park (GSTeP), Scientific Directorate, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
- Bioinformatics Research Core Facility, Gemelli Science and Technology Park (GSTeP), Scientific Directorate, Policlinico Gemelli IRCCS Foundation, Rome, Italy.
- Institute of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
ORCID-Profile: Giulia Maneri, Camilla Nero, Luciano Giacò, Giovanni Scambia, Angelo Minucci
Zitieren
APA
Maneri, G., Nero, C., Giacò, L., Scambia, G., & Minucci, A. (2024). Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae096
Vancouver
Maneri G, Nero C, Giacò L, Scambia G, Minucci A. Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae096
BibTeX
@article{Maneri2024,
author = {Maneri, Giulia and Nero, Camilla and Giacò, Luciano and Scambia, Giovanni and Minucci, Angelo},
title = {Germline reflex BRCA1/2 testing following tumor-only comprehensive genomic profiling: why, when, and how},
journal = {JNCI Cancer Spectrum},
year = {2024},
doi = {10.1093/jncics/pkae096}
}
EUVIMED